Diabetes

Around 11% of patients who use insulin have adverse drug reactions.

Lixisenatide is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist.

The FDA is considering approval for Sanofi's lixisenatide type 2 diabetes treatment.

Tresiba and Ryzodeg were originally denied approval due to adverse cardiovascular effects.

Eli Lilly and Company has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.

Discovery could lead to treatments that stop cancer recurrence.

The FDA today approved insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg) to improve glucose control in adults with diabetes.

Merck has provided an update on its diabetes portfolio and re-affirmed the company's comprehensive, long-term commitment to patients with diabetes.

Type 2 diabetes drug canagliflozin (Invokana, Invokamet) can decrease bone strength and increase the risk of fractures, the FDA is warning health care professionals.

Use of diabetes therapy may increase the risk of bone fracture.

Jessica Kerr, PharmD, CDE, and assistant department chair at Southern Illinois University Edwardsville discusses what patients should know about Afrezza.

Tumors linked to high blood sugar can be successfully treated without affecting blood vessel growth.

Kristene Diggins, FAANP, CNE, NEA-BC, DNP, DCC, MBA, manager of professional practice at MinuteClinic, talks obstacles to managing diabetes, and how pharmacists overcome them.

Jessica Kerr, PharmD, CDE, and assistant department chair at Southern Illinois University Edwardsville discusses potential barriers to inhaled insulin, like Afrezza.

Discovery holds promise for patients with Crohn's disease, diabetes, ulcerative colitis, and more.

Kristene Diggins, FAANP, CNE, NEA-BC, DNP, DCC, MBA, manager of professional practice at MinuteClinic, gives counseling points that pharmacists should provide to diabetic patients.

HbA1C significantly decreased in adults with poorly controlled type 2 diabetes.

Jessica Kerr, PharmD, CDE, and assistant department chair at Southern Illinois University Edwardsville talks about information pharmacists should give patients on high-dose basal insulin.

Health care professionals advised to discontinue drug regimen when appropriate.

Kristene Diggins, FAANP, CNE, NEA-BC, DNP, DCC, MBA, manager of professional practice at MinuteClinic, talks about the benefits and risks of aggressive glycemic controls.

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes may cause severe and disabling joint pain, the FDA has warned.

Adding Afrezza insulin inhalation powder to oral diabetes medications significantly reduces HbA1C in adults with poorly controlled type 2 diabetes.

Jessica Kerr, PharmD, CDE, and assistant department chair at Southern Illinois University Edwardsville talks about the biggest roadblocks to controlling type 2 diabetes.

Device may eventually detect cancer and diabetes.